Efficacy of 10-day decitabine in acute myeloid leukemia-Reference-Cited by-同舟云学术

Efficacy of 10-day decitabine in acute myeloid leukemia

Published:2021-04 Issue: Volume:103 Page:106524
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Bouligny Ian M.^ORCID,Mehta Vivek,Isom Scott^ORCID,Ellis Leslie R.,Bhave Rupali R.,Howard Dianna S.^ORCID,Lyerly Susan,Manuel Megan,Dralle Sarah,Powell Bayard L.,Pardee Timothy S.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference36 articles.

1. The molecular pathology of acute myeloid leukemia;Licht;Hematology Am. Soc. Hematol. Educ. Program,2005

2. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations;Lindsley;Blood,2015

3. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings;Ball;Leuk. Lymphoma,2017

4. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy;Christman;Oncogene,2002

5. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines;Hollenbach;PLoS One,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review;Cytotherapy;2024-05

2. Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment;Therapeutic Advances in Hematology;2023-01

3. Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms;Holland‐Frei Cancer Medicine;2022-10-21

4. Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia;Clinical Cancer Research;2022-02-21

5. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia;Journal for ImmunoTherapy of Cancer;2022-01